Canaccord Genuity Raises Price Target on BioMarin Pharma (BMRN) Following BMN-111 Data
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
BMN 111 (vosoritide) Improves Growth Velocity in Children With Achondroplasia in Phase 2 Study
June 17, 2015 4:01 PM EDT- 50% Increase in mean annualized growth velocity in 15 µg/kg/daily dose group
- BMN 111 was well tolerated across all three dose cohorts
- Phase 2 findings support program advancement of 15µg/kg/daily dose into pivotal registration discussions with health authorities
- Investor conference call to be held today, June 17, 2015 at 1:30pm PT/(4:30pm ET)
SAN RAFAEL, Calif., June 17, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced positive results of a Phase 2 proof-of-concept and dose finding study of BMN 111... More
